Skip to main content

Advertisement

SpringerLink
Log in

The impact of surgery in oligometastatic prostate cancer

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

Oligometastatic prostate cancer has been considered an intermediate state between localized disease and widespread metastases, but there is no consensus on the definition of oligometastasis in prostate cancer. At present, a clinical diagnosis made on the basis of up to five extrapelvic lesions is reasonable for use. Retrospective studies and post hoc analyses suggest that local or metastasis-directed interventions could have benefits in the oligometastatic state including a better response to systematic therapy, lower risk of local complications, and possible positive impact on cancer-specific survival and overall survival; however, insufficient data are available to draw reliable conclusions. In this short review, we summarize the current available data on the role of surgery in oligometastatic prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

PCa:

Prostate cancer

RP:

Radical prostatectomy

mCRPC:

Metastastic castration-refractory prostate cancer

ADT:

Androgen-deprivation therapy

OS:

Overall survival

CSS:

Cancer specific survival

PCSM:

Prostate cancer specific mortality

References

  1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E86.

    Article  CAS  PubMed  Google Scholar 

  2. James ND, Spears MR, Clarke NW, et al. Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel era”: data from 917 patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). Eur Urol. 2015;67(6):1028–38.

    Article  PubMed  Google Scholar 

  3. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.

    Article  CAS  PubMed  Google Scholar 

  4. Tosoian JJ, Gorin MA, Ross AE, et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat Rev Urol. 2017;14(1):15–25.

    Article  CAS  PubMed  Google Scholar 

  5. Ost P, Jereczek-Fossa BA, As NV, et al. Progression-free survival following stereotactic body radiotherapy for oligometastatic prostate cancer treatment-naive recurrence: a multi-institutional analysis. Eur Urol. 2016;69(1):9–12.

    Article  PubMed  Google Scholar 

  6. Schick U, Jorcano S, Nouet P, et al. Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases. Acta Oncol. 2013;52(8):1622–8.

    Article  CAS  PubMed  Google Scholar 

  7. Ahmed KA, Barney BM, Davis BJ, et al. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol. 2012;2:215.

    Article  CAS  PubMed  Google Scholar 

  8. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–44.

    Article  CAS  PubMed  Google Scholar 

  9. Sridharan S, Steigler A, Spry NA, et al. Oligometastatic bone disease in prostate cancer patients treated on the TROG 03.04 RADAR trial. Radiother Oncol. 2016;121(1):98–102.

    Article  PubMed  Google Scholar 

  10. Singh D, Yi WS, Brasacchio RA, et al. Is there a favorable subset of patients with prostate cancer who develop oligometastases? Int J Radiat Oncol Biol Phys. 2004;58(1):3–10.

    Article  PubMed  Google Scholar 

  11. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.

    Article  PubMed  Google Scholar 

  12. Maurer T, Eiber M, Schwaiger M, et al. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13(4):226–35.

    Article  CAS  PubMed  Google Scholar 

  13. Aus G, Hugosson J, Norlen L. Need for hospital care and palliative treatment for prostate cancer treated with noncurative intent. J Urol. 1995;154(2 Pt 1):466–9.

    Article  CAS  PubMed  Google Scholar 

  14. Patrikidou A, Brureau L, Casenave J, et al. Locoregional symptoms in patients with de novo metastatic prostate cancer: morbidity, management, and disease outcome. Urol Oncol. 2015;33(5):202 e9–202 e17.

    Article  Google Scholar 

  15. Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139(7):1315–26.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Danna EA, Sinha P, Gilbert M, et al. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res. 2004;64(6):2205–11.

    Article  CAS  PubMed  Google Scholar 

  17. Tzelepi V, Efstathiou E, Wen S, et al. Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol. 2011;29(18):2574–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Temple LK, Hsieh L, Wong WD, et al. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol. 2004;22(17):3475–84.

    Article  PubMed  Google Scholar 

  19. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59.

    Article  PubMed  Google Scholar 

  20. Mickisch GH, Garin A, van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001;358(9286):966–70.

    Article  CAS  PubMed  Google Scholar 

  21. Ghavamian R, Bergstralh EJ, Blute ML, et al. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol. 1999;161(4):1223–7. discussion 7–8.

    Article  CAS  PubMed  Google Scholar 

  22. Thompson IM, Tangen C, Basler J, et al. Impact of previous local treatment for prostate cancer on subsequent metastatic disease. J Urol. 2002;168(3):1008–12.

    Article  PubMed  Google Scholar 

  23. Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058–66.

    Article  PubMed  Google Scholar 

  24. Gratzke C, Engel J, Stief CG. Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol. 2014;66(3):602–3.

    Article  PubMed  Google Scholar 

  25. Engel J, Bastian PJ, Baur H, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol. 2010;57(5):754–61.

    Article  PubMed  Google Scholar 

  26. Moschini M, Briganti A, Murphy CR, et al. Outcomes for patients with clinical lymphadenopathy treated with radical prostatectomy. Eur Urol. 2016;69(2):193–6.

    Article  PubMed  Google Scholar 

  27. Won AC, Gurney H, Marx G, et al. Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int. 2013;112(4):E250–E5.

    Article  PubMed  Google Scholar 

  28. Heidenreich A, Pfister D, Porres D. Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol. 2015;193(3):832–8.

    Article  PubMed  Google Scholar 

  29. Jang WS, Kim MS, Jeong WS, et al. Does robot-assisted radical prostatectomy benefit patients with prostate cancer and bone oligometastases? BJU Int. 2018;121(2):225–31.

    Article  PubMed  Google Scholar 

  30. Yao HH, Hong M, Corcoran NM, et al. Advances in local and ablative treatment of oligometastasis in prostate cancer. Asia Pac J Clin Oncol. 2014;10(4):308–21.

    Article  PubMed  Google Scholar 

  31. Chao DH, Higgins JP, Brooks JD. Biochemical remission after resection of prostate cancer lung metastasis. Urology. 2004;63(3):584–5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Medical University of Innsbruck, Anichstraße 35, 6020, Innsbruck, Austria

    Jasmin Bektic MD &  Wolfgang Horninger MD

Authors
  1. Jasmin Bektic MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wolfgang Horninger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jasmin Bektic MD.

Ethics declarations

Conflict of interest

J. Bektic and W. Horninger declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bektic, J., Horninger, W. The impact of surgery in oligometastatic prostate cancer. memo 11, 305–308 (2018). https://doi.org/10.1007/s12254-018-0456-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-018-0456-3

Keywords

Search

Navigation